The American pharmaceutical Moderna had a profit of 79 million dollars between January and March, far from the 3,657 million (3,318 million euros) that it earned in the first quarter of last year thanks to the sales of its vaccine against Covid-19, but above market expectations.
With the pandemic under control and the consequent drop in vaccine sales, Moderna had a turnover of 1,862 million dollars in the first three months of the year, compared to 6,066 million a year ago.
Those revenues were higher than expected by analysts, thanks in large part to payments on deferred 2022 vaccine contracts, sending shares of the company higher on Wall Street, which were up 3.4% half an hour after the announcement. opening.
Read more: Director of PAHO believes it is convenient to maintain a health emergency due to Covid-19
Moderna profit falls due to lower sales of vaccines
For the whole of this year, Moderna maintained its forecast of entering about 5,000 million dollars thanks to the vaccine against Covid-19.
The company, in a statement, was optimistic about new contracts it is signing in the United States for the fall and said it is also in similar talks in other markets such as Japan, the European Union and Australia.
In addition, Moderna is preparing the potential launch in 2024 of an adult respiratory syncytial virus (RSV) vaccine and other new products.
With information from EFE.
It may interest you:
2023-05-04 16:16:58
#Moderna #profit #plummets #vaccine #sales
